October 2, 2014
  • RA2 DREAM Challenge

    RA2 DREAM Challenge: Automated Scoring of Radiographic Joint Damage

    Launch: November 4, 2019 (Now open)
    Final Submissions: May 31, 2020
    Winners Announced: July 31, 2020

    Rheumatoid Arthritis (RA) is a debilitating disease that causes joint damage in the hands and feet due to inflammation. Accurate measuring of joint damage and progression of disease is essential in assessing the severity of disease, along with being able to monitor patient response to treatment. Scoring of X-ray images is tedious and there can be a great deal of variability between rheumatologists when applying scoring methods. We will leverage nearly 1000 images across a range of disease severities to challenge participants to develop an automated scoring algorithm with the goal of making clinical scoring fast and consistent; this will aid rheumatologists in making the best decisions for patients.

     

  • Allen Institute Cell Lineage Reconstruction DREAM Challenge

    Allen Institute Cell Lineage Reconstruction DREAM Challenge

    Registration Opens: September, 2019
    Launch: Mid-October, 2019 (Now Open)
    Final Submissions: January, 2020
    Winners Announced: March, 2020

    CRISPR-based molecular tools allow the reconstruction of cell lineages based on the phylogenetic analysis of DNA mutations induced by CRISPR during development. The challenge - a partnership between The Allen Institute and DREAM - will comprise 3 subchallenges focused on reconstructing cell lineage trees of different sizes and nature. Through the usage for training purposes of experimental and in silico generated data sets, the goal of this challenge is to mobilize a larger community for evaluating new optimal tree-building methods.

  • The EHR DREAM Challenge

    The EHR DREAM Challenge

    Registration OPEN
    Launch October 9, 2019
    Final submissions January 9, 2020
    Results announced February 9, 2020

    The goals of the EHR DREAM Challenge are to prospectively predict patient health outcomes in order to 1) lower the barriers to piloting innovative machine learning and data science methods in healthcare, 2) establish clinically relevant prediction benchmarks and evaluation metrics, and 3) minimize the distance between model developers and the clinic to reduce the time for model implementation.

     

  • Single Cell Signaling in Breast Cancer

    Single Cell Signaling in Breast Cancer

    Launch: August 2, 2019 (now open)
    Webinar: August 20, 2019

    This challenges uses genomic, transcriptomic, and proteomic measurements to evaluate signaling responses of 67 well-characterized breast cell lines to drug treatment at the single-cell level to better understand single-cell signaling and signaling modeling.

  • Tumor Deconvolution DREAM Challenge

    Tumor Deconvolution DREAM Challenge

    Launch:  June 3, 2019 (Challenge Now Open!)
    Webinar: June 5, 2019

    The goal of this Challenge is to evaluate the ability of computational methods to deconvolve bulk expression data, reflecting a mixture of cell types, into individual immune components.

Designed and run by a community of researchers from a variety of organizations, DREAM Challenges invite participants to propose solutions to fundamental biomedical questions — fostering collaboration and building communities in the process. Sage Bionetworks provides the expertise and infrastructure to host challenges via their Synapse platform. Together, we share a vision allowing individuals and groups to collaborate openly so that the “wisdom of the crowd” provides the greatest impact on science and human health.

If you have an idea for a DREAM challenge, please contact us here.

FEATURED PUBLICATION

Guinney J, Saez-Rodriguez J.; Alternative models for sharing confidential biomedical data.; Nat Biotechnol. 2018 May 9;36(5):391-392. doi: 10.1038/nbt.4128.  

FEATURED CONTENT

The participants in the Annual DREAM Conference in NYC in Nov helped us "crowdsource" our latest video. Thanks to all that allowed us to take your pictures or sent in pictures!  

DREAM Conference Info

RSG with DREAM Conference is its 12th year! This premier annual meeting for DREAM will be the culmination of three DREAM Challenges with presentations by their best performers. There will also be Keynotes and Open Papers presented. Please join us in NYC at MSK on Nov 4, 2019.
November 8, 2019

DREAM Challenges Announces Changes in its Leadership that Support a Rich Future in Open Benchmarking

FOR IMMEDIATE RELEASE

SEATTLE – DREAM Challenges has announced changes to its governance and leadership to reflect its vision for future growth. DREAM is a volunteer organization of more than 30,000 solvers focused on crowd-sourced challenges to benchmark informatic algorithms in biomedicine. The peer-based governance process has been formalized by charter and will be led by a volunteer board of directors, with a rotating chair position. Dr. Justin Guinney, VP of Computational Oncology at Sage Bionetworks, is the new chair.

Sage Bionetworks has partnered with DREAM since 2013, providing the technology platform, governance protocols, and data science expertise that underpin DREAM Challenges. The DREAM methodology has already been adopted by other groups that host challenges. By assuming a key role in the charter, Sage is making a clear commitment to upholding and growing DREAM’s mission to enable collaborative science.

DREAM was founded in 2006 by Dr. Gustavo Stolovitzky, who announced this week at the 14th DREAM Challenges Conference in New York that he would be stepping back from actively leading the organization, though he will remain involved. Dr. Stolovitzky, the Director of the IBM Translational Systems Biology and Nanobiotechnology Program at IBM’s Thomas J. Watson Research Center, will continue to support the mission of DREAM as Chair Emeritus and DREAM Board Director.

“I’m proud of the community we’ve created with the DREAM Challenges,” said Dr. Stolovitzky. “Our approach has confirmed that data sharing and collaborative science is a powerful methodology not only for scientific research but also for the rigorous evaluation of algorithmic performance that is necessary for reproducible science. There is much to discover yet and it will be a pleasure to watch DREAM evolve under Justin Guinney’s creative leadership.”

Dr. Guinney, who has served on the DREAM board since in 2013, will work closely with Dr. Stolovitzky and the board to develop a vision for how to extend the reach of DREAM Challenges to untapped domains that are poised to benefit from crowd-sourced solutions. Dr. Guinney’s contributions to DREAM have focused on advanced predictive modeling in diagnostic mammography screening and drug combination therapy; prognostic modeling in breast and prostate cancer and multiple myeloma; and, recently, a benchmarking challenge using electronic healthcare records.

“The power of DREAM is the power to connect,” said Dr. Guinney, whose work at Sage Bionetworks focuses on integrative data analysis for prognostic and predictive modeling of cancer outcomes and response to therapy. “Building on the foundation of our past successes, DREAM will continue to serve its mission of connecting individuals and teams with data and algorithms to tackle complex biomedical questions.”

Under Dr. Stolovitzky’s leadership, DREAM evolved into a model of how to use crowdsourcing and open science in biomedicine, with first-of-its-kind Challenges that led to scientific insights in a wide range of research topics including biological network inference, cancer genomics and pharmacogenomics, predicting disease progression, and medical imaging among others. DREAM has launched more than 60 challenges that have engaged and touched the careers of thousands of scientists from dozens of institutions across the public and private sectors around the world.

“Having been involved with DREAM all these years, it’s an honor to help usher in the next generation of Challenges,” said Dr. Guinney.

In addition to Drs. Guinney and Stolovitzky, other board directors include: Dr. Laura Heiser, Oregon Health Sciences University; Dr. Paul Boutros, University of California, Los Angeles; Dr. James Costello, University of Colorado; Dr. Pablo Meyer, IBM; and Dr. Julio Saez-Rodriguez, Heidelberg University. More information about the DREAM leadership and governance can be found at www.dreamchallenges/people.


ABOUT DREAM CHALLENGES

DREAM (Dialogue on Reverse Engineering and Assessment Methods) Challenges emerged in 2006 to leverage the wisdom of the multidisciplinary scientific community to solve fundamental and difficult questions in biomedical research. DREAM’s methodology is based on crowd-sourcing scientific Challenges, fostering open and collaborative research, and promoting data sharing. In 2013, DREAM partnered with Sage Bionetworks, which developed and administers the technology platform that underpins DREAM Challenges.

ABOUT SAGE BIONETWORKS

Sage Bionetworks is a nonprofit biomedical research and technology development organization that was founded in Seattle in 2009. Our focus is to develop and apply open practices to data-driven research for the advancement of human health. Our interdisciplinary team of scientists and engineers work together to provide researchers access to technology tools and scientific approaches to share data, benchmark methods, and explore collective insights, all backed by Sage’s gold-standard governance protocols and commitment to user-centered design. Sage is a 501c3 and is supported through a portfolio of competitive research grants, commercial partnerships, and philanthropic contributions.

Contact: Hsiao-Ching Chou
chou@sagebionetworks.org

May 30, 2019

Idea Competition Winner Announced for the CTSA Program

The CD2H Idea Competition for the CTSA Program is pleased to announce the winner of the Idea Challenge Competition: University of Alabama, Birmingham “Automated Scoring of Radiographic Damage in Rheumatoid Arthritis” (PI S. Louis Bridges). This will be developed into an upcoming DREAM Challenge. (read more)

February 26, 2019

PrecisionFDA and NCI CPTAC Announce the Best Performers in Multi-omics Sample Mislabeling Big Data Challenge

PrecisionFDA and the National Cancer Institute’s (NCI) Clinical Proteomic Tumor Analysis Consortium (CPTAC) (in coordination with DREAM Challenges) are pleased to announce the Best Performers in the first-ever Crowdsourced Multi-omics Sample Mislabeling Big Data Challenge. This unique challenge utilized proteogenomic datasets generated by CPTAC and clinical annotation information. A total of 230 submissions from participants around the globe were received and evaluated. Subchallenge 1 focused on the development of next-gen computational models for detecting mislabeled samples using proteomic and clinical data generated by CPTAC, while Subchallenge 2 took a step further, aiming to identify and correct mismatched samples with one data type mislabeled among three data types (clinical, transcriptomic, and proteomic data). Visit us to learn more about this big data computational multi-omics challenge and its best performers and come here them their findings at  DREAM Challenges@RECOMB 2019. (learn more)